Cargando…
Evaluation of the effectiveness and safety of glucocorticoids intravitreal implant therapy in macular edema due to retinal vein occlusion
The purpose of this study was to evaluate the impact of intravitreal dexamethasone implant (Ozurdex) on macular morphology and functions in eyes with macular edema (ME) secondary to retinal vein occlusion. Efficacy outcomes of the treatment were best-corrected visual acuity (BCVA) and central retina...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4887062/ https://www.ncbi.nlm.nih.gov/pubmed/27307716 http://dx.doi.org/10.2147/CIA.S96674 |
_version_ | 1782434691201105920 |
---|---|
author | Michalska-Małecka, Katarzyna Gaborek, Aneta Nowak, Mariusz Halat, Tomasz Pawłowska, Mariola Śpiewak, Dorota |
author_facet | Michalska-Małecka, Katarzyna Gaborek, Aneta Nowak, Mariusz Halat, Tomasz Pawłowska, Mariola Śpiewak, Dorota |
author_sort | Michalska-Małecka, Katarzyna |
collection | PubMed |
description | The purpose of this study was to evaluate the impact of intravitreal dexamethasone implant (Ozurdex) on macular morphology and functions in eyes with macular edema (ME) secondary to retinal vein occlusion. Efficacy outcomes of the treatment were best-corrected visual acuity (BCVA) and central retinal thickness (CRT). Safety outcomes were intraocular pressure and cornea endothelial cell density. The study was conducted by the prospective analysis on 36 patients (17 women and 19 men) aged 28–77 years (the average age was 58±15 years) treated with the injection of dexamethasone implant because of the persistent ME at the Department of Ophthalmology and Ophthalmology Outpatient Clinic of the University Centre of Ophthalmology and Oncology in Katowice. The studied group included 16 patients with central retinal vein occlusion (16 eyes), and 20 patients with branch retinal vein occlusion (20 eyes). We found a significant increase of BCVA after first, second, and third month of treatment. Six months after the treatment, BCVA decreased, although not significantly compared with the value obtained in the third month. Two months after the intravitreal implantation of dexamethasone delivery system, CRT was 338±163 μm and was significantly lower compared with pretreatment value. Between third and sixth month after the treatment, we found insignificant increase of CRT compared with thickness observed in second month. Two months after the treatment, we found an increase in intraocular pressure in 36% of cases and a further decrease during the final visit 6 months after the treatment. During the treatment, there were no significant differences in endothelial cell density in branch retinal vein occlusion and central retinal vein occlusion. We found the intravitreal dexamethasone implant to be safe, well tolerated, and likely to lead to fast morphological and functional improvement of the macula and visual rehabilitation in patients with ME due to retinal vein occlusion. |
format | Online Article Text |
id | pubmed-4887062 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2016 |
publisher | Dove Medical Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-48870622016-06-15 Evaluation of the effectiveness and safety of glucocorticoids intravitreal implant therapy in macular edema due to retinal vein occlusion Michalska-Małecka, Katarzyna Gaborek, Aneta Nowak, Mariusz Halat, Tomasz Pawłowska, Mariola Śpiewak, Dorota Clin Interv Aging Original Research The purpose of this study was to evaluate the impact of intravitreal dexamethasone implant (Ozurdex) on macular morphology and functions in eyes with macular edema (ME) secondary to retinal vein occlusion. Efficacy outcomes of the treatment were best-corrected visual acuity (BCVA) and central retinal thickness (CRT). Safety outcomes were intraocular pressure and cornea endothelial cell density. The study was conducted by the prospective analysis on 36 patients (17 women and 19 men) aged 28–77 years (the average age was 58±15 years) treated with the injection of dexamethasone implant because of the persistent ME at the Department of Ophthalmology and Ophthalmology Outpatient Clinic of the University Centre of Ophthalmology and Oncology in Katowice. The studied group included 16 patients with central retinal vein occlusion (16 eyes), and 20 patients with branch retinal vein occlusion (20 eyes). We found a significant increase of BCVA after first, second, and third month of treatment. Six months after the treatment, BCVA decreased, although not significantly compared with the value obtained in the third month. Two months after the intravitreal implantation of dexamethasone delivery system, CRT was 338±163 μm and was significantly lower compared with pretreatment value. Between third and sixth month after the treatment, we found insignificant increase of CRT compared with thickness observed in second month. Two months after the treatment, we found an increase in intraocular pressure in 36% of cases and a further decrease during the final visit 6 months after the treatment. During the treatment, there were no significant differences in endothelial cell density in branch retinal vein occlusion and central retinal vein occlusion. We found the intravitreal dexamethasone implant to be safe, well tolerated, and likely to lead to fast morphological and functional improvement of the macula and visual rehabilitation in patients with ME due to retinal vein occlusion. Dove Medical Press 2016-05-23 /pmc/articles/PMC4887062/ /pubmed/27307716 http://dx.doi.org/10.2147/CIA.S96674 Text en © 2016 Michalska-Małecka et al. This work is published and licensed by Dove Medical Press Limited The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. |
spellingShingle | Original Research Michalska-Małecka, Katarzyna Gaborek, Aneta Nowak, Mariusz Halat, Tomasz Pawłowska, Mariola Śpiewak, Dorota Evaluation of the effectiveness and safety of glucocorticoids intravitreal implant therapy in macular edema due to retinal vein occlusion |
title | Evaluation of the effectiveness and safety of glucocorticoids intravitreal implant therapy in macular edema due to retinal vein occlusion |
title_full | Evaluation of the effectiveness and safety of glucocorticoids intravitreal implant therapy in macular edema due to retinal vein occlusion |
title_fullStr | Evaluation of the effectiveness and safety of glucocorticoids intravitreal implant therapy in macular edema due to retinal vein occlusion |
title_full_unstemmed | Evaluation of the effectiveness and safety of glucocorticoids intravitreal implant therapy in macular edema due to retinal vein occlusion |
title_short | Evaluation of the effectiveness and safety of glucocorticoids intravitreal implant therapy in macular edema due to retinal vein occlusion |
title_sort | evaluation of the effectiveness and safety of glucocorticoids intravitreal implant therapy in macular edema due to retinal vein occlusion |
topic | Original Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4887062/ https://www.ncbi.nlm.nih.gov/pubmed/27307716 http://dx.doi.org/10.2147/CIA.S96674 |
work_keys_str_mv | AT michalskamałeckakatarzyna evaluationoftheeffectivenessandsafetyofglucocorticoidsintravitrealimplanttherapyinmacularedemaduetoretinalveinocclusion AT gaborekaneta evaluationoftheeffectivenessandsafetyofglucocorticoidsintravitrealimplanttherapyinmacularedemaduetoretinalveinocclusion AT nowakmariusz evaluationoftheeffectivenessandsafetyofglucocorticoidsintravitrealimplanttherapyinmacularedemaduetoretinalveinocclusion AT halattomasz evaluationoftheeffectivenessandsafetyofglucocorticoidsintravitrealimplanttherapyinmacularedemaduetoretinalveinocclusion AT pawłowskamariola evaluationoftheeffectivenessandsafetyofglucocorticoidsintravitrealimplanttherapyinmacularedemaduetoretinalveinocclusion AT spiewakdorota evaluationoftheeffectivenessandsafetyofglucocorticoidsintravitrealimplanttherapyinmacularedemaduetoretinalveinocclusion |